Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon
BackgroundA national Oral Cholera Vaccine (OCV) Euvichol-Plus® campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1480744/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846162570469179392 |
|---|---|
| author | Abeer Zeitoun Aya Ibrahim Sarah Reda El Sayed Eva Hobeika Rita Karam Rita Karam Rita Karam |
| author_facet | Abeer Zeitoun Aya Ibrahim Sarah Reda El Sayed Eva Hobeika Rita Karam Rita Karam Rita Karam |
| author_sort | Abeer Zeitoun |
| collection | DOAJ |
| description | BackgroundA national Oral Cholera Vaccine (OCV) Euvichol-Plus® campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events reports, received at the Lebanese National Pharmacovigilance Program’s (LNPVP) passive surveillance system.MethodsCase reports were extracted from the LNPVP’s database. SPSS software was used to perform statistical analysis, with categorical variables compared using Pearson’s χ2 test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine.ResultsA total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11 years old (41.3%). Reporters’ age range was 1–74 years old.ConclusionMonitoring AEFIs through the cholera outbreak’s emergency campaign favors the safety profile of OCV. |
| format | Article |
| id | doaj-art-bb2400ffa56a42f1adc209a892d6b014 |
| institution | Kabale University |
| issn | 2296-2565 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj-art-bb2400ffa56a42f1adc209a892d6b0142024-11-20T06:27:43ZengFrontiers Media S.A.Frontiers in Public Health2296-25652024-11-011210.3389/fpubh.2024.14807441480744Descriptive analysis of adverse events following immunization with oral cholera vaccine in LebanonAbeer Zeitoun0Aya Ibrahim1Sarah Reda El Sayed2Eva Hobeika3Rita Karam4Rita Karam5Rita Karam6Quality Assurance of Pharmaceutical Products Department, National Pharmacovigilance Program, Lebanese Ministry of Public Health, Beirut, LebanonQuality Assurance of Pharmaceutical Products Department, National Pharmacovigilance Program, Lebanese Ministry of Public Health, Beirut, LebanonQuality Assurance of Pharmaceutical Products Department, National Pharmacovigilance Program, Lebanese Ministry of Public Health, Beirut, LebanonFaculty of Arts and Sciences, Holy Spirit University of Kaslik, Beirut, LebanonQuality Assurance of Pharmaceutical Products Department, National Pharmacovigilance Program, Lebanese Ministry of Public Health, Beirut, LebanonDepartment of Chemistry and Biochemistry, Faculty of Sciences, Lebanese University, Beirut, LebanonPharmacology Department, Faculty of Medical Sciences, Lebanese University, Beirut, LebanonBackgroundA national Oral Cholera Vaccine (OCV) Euvichol-Plus® campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events reports, received at the Lebanese National Pharmacovigilance Program’s (LNPVP) passive surveillance system.MethodsCase reports were extracted from the LNPVP’s database. SPSS software was used to perform statistical analysis, with categorical variables compared using Pearson’s χ2 test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine.ResultsA total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11 years old (41.3%). Reporters’ age range was 1–74 years old.ConclusionMonitoring AEFIs through the cholera outbreak’s emergency campaign favors the safety profile of OCV.https://www.frontiersin.org/articles/10.3389/fpubh.2024.1480744/fulloral cholera vaccineadverse events following immunizationvaccinespharmacovigilancecholeradescriptive analysis |
| spellingShingle | Abeer Zeitoun Aya Ibrahim Sarah Reda El Sayed Eva Hobeika Rita Karam Rita Karam Rita Karam Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon Frontiers in Public Health oral cholera vaccine adverse events following immunization vaccines pharmacovigilance cholera descriptive analysis |
| title | Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon |
| title_full | Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon |
| title_fullStr | Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon |
| title_full_unstemmed | Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon |
| title_short | Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon |
| title_sort | descriptive analysis of adverse events following immunization with oral cholera vaccine in lebanon |
| topic | oral cholera vaccine adverse events following immunization vaccines pharmacovigilance cholera descriptive analysis |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1480744/full |
| work_keys_str_mv | AT abeerzeitoun descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT ayaibrahim descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT sarahredaelsayed descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT evahobeika descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT ritakaram descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT ritakaram descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon AT ritakaram descriptiveanalysisofadverseeventsfollowingimmunizationwithoralcholeravaccineinlebanon |